Chiff.com

The web, reviewed by humans since 1999.






Health
baby
Pregnancy
baby's first year
baby names
baby nursery
c-sections
childbirth & labor
how to get pregnant
midwives
morning sickness
natural childbirth
postpartum depression
pregnancy complications
pregnancy forums
pregnancy & nutrition
pregnancy stages
premature labor - 17P
sonograms
stretch marks
twins & triplets
working & pregnant

MAIN Arrow to Health Health Arrow to Pregnancy Pregnancy Arrow to 17P therapy17P - Progesterone Therapy, Premature Labor



Studies show the benefits of
progesterone therapy to help
prevent preterm births like
this "preemie" born 8 weeks
early & weighing about 4 lbs.



Every year in the United States, half a million babies are born prematurely.

Researchers have identified a therapy that has the potential to prevent thousands of these early deliveries.

The drug is 17 Alpha-hydroxyprogesterone caproate, known as 17P.

Preterm deliveries rising

About 8 percent of babies born earlier than the 37th week of pregnancy will have a birth defect according to the research by a team of investigators from the March of Dimes, the U.S. Centers for Disease Control and Prevention (CDC), and several other major institutions.

No one knows the causes, but the rate of premature deliveries in the United States is rising. A National Center for Health Statistics report, Births: Final data for 2006, National Vital Statistics Reports; Vol. 57, No. 7, shows that the preterm birth rate rose to 12.8 percent in 2006 — a 36 percent increase since the early 1980s.

17P is effective

One study, reported in the New England Journal of Medicine (N Engl J Med 2003; 348:2379-85), showed that 17P treatment reduced preterm birth by 34 percent in women pregnant with a single baby who had a previous preterm delivery (one indicator of high risk for early labor in following pregnancies).

Women who received weekly 17P injections starting at 16 to 20 weeks’ gestation had a significantly reduced risk of preterm delivery compared to women who received placebo injections. Infants whose mothers were treated with 17P also had significantly lower rates of severe complications.

The children of the women who participated in the 2003 NIHCD showed no significant difference in the frequency of genital malformations between children who had been exposed in utero to 17P and children whose mothers had been given placebo. A follow up study of these children at 4 years showed that height, weight, head circumference, blood pressure, neurodevelopment, and scores for gender specific roles were comparable between the two groups

How does 17P work?

Researchers are not absolutely certain why the progesterone based treatment works. They do know that in most mammals, progesterone is produced by the placenta during pregnancy. Medical researchers believe that this hormone helps keep the uterus in a quiescent state — preventing the contractions that lead to labor.

A drop in the blood level of progesterone results in uterine contractions and labor (J Soc Gynecol Invest 2002; 9:125-36). It seems that supplementing the levels of progesterone, by administering 17P to women who are experiencing early labor, helps to keep the uterus from contracting and, in many cases, delays labor until the baby is safe.

17P is normally prescribed as a series of shots given weekly. The treatment begins between the 16th and 21st week of pregnancy. Multiple studies have found that women who received at least five injections of 17P, experienced a statistically significant reduction in NICU admissions and in preterm births.

17P does not prevent preterm deliveries with multiples

Women who are pregnant with twins or multiples should not take 17P. Despite the low risk for side effects, it has not been shown to be more effective than a placebo in reducing the risk of preterm labor with multiples. Only women with a singleton pregnancy and who have a history of a previous singleton spontaneous preterm birth between 20 and weeks gestation are good candidates for 17P treatments.



17P is not effective in preterm delivery with twins


Does this help prevent early delivery due to incompetent or short cervix?

Doctors and researchers are uncertain about whether progesterone therapy should be used with women who are in danger of early labor due to problems with the cervix. A 2007 study found that daily vaginal administration of 200 mg of progesterone reduced the rate of delivery before 34 weeks from 34% to 19% in women with a short cervix (N Eng J Med. 2007;357:462-469). The data is inconclusive and some recent studies have not found significant results. The American College of Obstetricians and Gynecologists allows 17P therapy for women with an incompetent or short cervix since there is a chance that the treatments will help and the risk of serious side effects is small.

Some studies suggest a procedure called cerclage, where the doctor puts a stitch in the cervix to help keep it closed until the baby is able to thrive outside the uterus (usually around the 37th week), may help reduce the risk of preterm delivery in some women who have cervical abnormalities and have had a previous preterm delivery.

How is the 17P treatment administered?

The progesterone preparation known as 17P is available only by prescription from compounding pharmacies that compound sterile products. It is normally dissolved in an oil suspension and given as a weekly shot into the muscle of the buttocks. !7P is also available as suppositories, although there is not enough research to determine whether that route is as effective as the injection.

Are there any side effects of 17P therapy?

The amount of progesterone produced during a normal pregnancy, mainly by the placenta, is greater than the pharmacologic doses employed in 17P treatments. Reported side effects in the mother have included swelling, itching and other local reactions at the site of the injection, hypersensitivity reactions, cough, dyspnea, and an increased risk of developing gestational diabetes.

More about 17P therapy around the Web:


 

Drugs In Pregnancy - 17 alpha-hydroxyprogesterone caproate (17OHPC)

Prevention of recurrent preterm birth

This information is intended as reference and not as medical advice.
All treatment decisions should be made in consultation with medical professionals.

 

Sponsored Links

Sponsored Links

 
 

chiff.com

Privacy  |  Mission Statement  |  Contact us |  Sitemap

All contents copyright © Chiff.com 1999 - 2017